Entity
OLT1177 (Dapansutrile) – Gasdermin D Inhibition & Pyroptosis Suppression
OLT1177 (dapansutrile) reportedly inhibits Gasdermin D-dependent IL-1β release and pyroptotic cell death in macrophages, according to a June 2026 preprint. The findings extend understanding of the compound's mechanism beyond NLRP3 inhibition and may support new therapeutic indications and IP claims in the inflammasome inhibitor space.
This page was written and is updated by the paper from the source articles listed below. Importance is how central the topic is to current coverage; confidence is how well-sourced the page is; mentions counts the articles that fed it. How the wiki works →
## Overview
OLT1177, also known as dapansutrile, is a small-molecule compound under investigation as an inhibitor of Gasdermin D (GSDMD)-dependent IL-1β release and pyroptotic cell death (bioRxiv:2026.05.31.729061). A June 2026 preprint reports experimental validation of its mechanism in bone marrow-derived macrophages.
## Mechanism of Action
Gasdermins are a family of pore-forming proteins that regulate release of the pro-inflammatory cytokine IL-1β from infected or PAMP-stimulated cells (bioRxiv:2026.05.31.729061). During infection or injury, IL-1β is released by both human and mouse macrophages. In mouse macrophages, this release is associated with pyroptosis — a form of inflammatory cell death. The process involves:
- **Caspase-1** processing of pro-IL-1β
- **GSDMD** pore formation as an exit channel for IL-1β
- OLT1177 reportedly inhibiting both processes in the context of LPS stimulation
## Therapeutic Relevance
The NLRP3 inflammasome / GSDMD / IL-1β axis is implicated in a wide range of inflammatory and autoimmune conditions, including gout, cardiovascular disease, and potentially sepsis. OLT1177 has been in earlier clinical-stage investigation as an NLRP3 inhibitor. The new mechanistic data on GSDMD-specific inhibition may broaden its therapeutic profile.
## IP and Commercial Landscape
For attorneys tracking pharmaceutical IP, the characterization of OLT1177's GSDMD inhibitory activity could support new patent claims (method of treatment, new indication) distinct from existing NLRP3-focused IP. Competitors in the inflammasome inhibitor space include AstraZeneca, Novartis, and several biotechs.
## Outlook
The pyroptosis and gasdermin field is rapidly evolving. GSDMD-targeted therapeutics represent an emerging drug class with multiple programs in development. This preprint may inform IND applications or clinical trial design for inflammatory disease indications.